Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antroquinonol - Golden Biotechnology Corporation

Next Previous
Drug Profile

Antroquinonol - Golden Biotechnology Corporation

Alternative Names: Hocena

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Golden Biotechnology Corporation
  • Developer China Sky One Medical; Golden Biotechnology Corporation; Queensland University of Technology
  • Class Alkenes; Anti-inflammatories; Antidementias; Antihyperlipidaemics; Antineoplastics; Antivirals; Cyclohexenes; Ketones; Skin disorder therapies; Small molecules
  • Mechanism of Action Epidermal growth factor receptor modulators; Mitogen-activated protein kinase modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Atopic dermatitis; Colorectal cancer; COVID-19 pneumonia; Hepatitis B; Hyperlipidaemia; Non-small cell lung cancer; Pancreatic cancer
  • No development reported Alzheimer's disease; Cancer

Most Recent Events

  • 18 Jan 2024 Pharmacokinetics and adverse events data from a phase I/II trial in Pancreatic cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 18 Jan 2024 Efficacy data from phase I/II clinical trials in Pancreatic cancer released by Golden Biotechnology
  • 16 Jun 2023 Golden Biotechnology Corporation completes a phase-II trial in Hepatitis B (In adults, In the elderly) in Taiwan (PO) (NCT03625102)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top